| |
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
Today’s Big NewsJan 23, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Kevin Dunleavy Department of Health and Human Services secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing Merck over the marketing and sale of one of its vaccines. RFK Jr.’s plans raise conflict-of-interest questions as he is seeking confirmation to run an agency that regulates vaccines. |
|
|
|
By Gabrielle Masson AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. |
By Conor Hale The medtech has tapped Katie Szyman for the role, who served as head of Edwards' critical care business, which was sold last year to BD. |
By Andrea Park With a large portion of people aged 45 and older prone to putting off or completely avoiding recommended colon cancer screenings, Exact Sciences is pitching its noninvasive at-home Cologuard test as a way to “skip the drama.” |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Fraiser Kansteiner Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions, while managing to stay true to its patient-centric ethos along the way. |
By Darren Incorvaia Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. |
By Conor Hale The company’s cobas liat system received a new 510(k) clearance from the FDA, as well as a waiver from CLIA mandates requiring that certain clinical tests be analyzed within a qualified laboratory. |
By Gabrielle Masson Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. |
By Nick Paul Taylor The Preeclampsia Foundation has found a formula for closing the maternal health equity gap: Mix one part equity-forward preeclampsia education with one part low-dose aspirin prophylaxis and voilà, you have GAP—SPIRIN, a campaign the nonprofit believes can address a persistent health inequity. |
By Nick Paul Taylor Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival antibody. |
By Zoey Becker More than 80 cases of treatment-associated anaphylaxis have been reported since 1996, according to the FDA's safety notice on Wednesday. The warning also applies to generics, including Sandoz's Glatopa. |
By Nick Paul Taylor Ab&B Bio-Tech has joined the stacked roster of biotechs queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with shots from companies including GSK, Merck & Co. and Pfizer. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
